This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo

The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.

The US Food and Drug Administration (FDA) has just approved a new drug for the treatment of schizophrenia. Marketed under the name Cobenfy, the medication combines two different drugs that together target a totally different mechanism in the brain than conventional antipsychotics,

Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company's new schizophrenia treatment,

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments